GlaxoSmithKline is one of the largest multinational pharmaceutical companies in China, with a total investment of over US$ 500 million in China and over 5,000 local employees. 1 Global full-featured R&D center and six major production bases: GlaxoSmithKline's operating company in China, GlaxoSmithKline (China) Investment Co., Ltd., Sino-American Tianjin SmithKline Pharmaceutical Co., Ltd. (joint venture), GlaxoSmithKline (Tianjin) Co., Ltd. (joint venture), GlaxoSmithKline Pharmaceutical (Suzhou) Co., Ltd., Shanghai GlaxoSmithKline Biological Products Co., Ltd. and GlaxoSmithKline Biological Products (Shenzhen) Co
In July 2007, GlaxoSmithKline China R&D Center was established in Shanghai, focusing on the research of neurodegenerative diseases, with the goal of developing new drugs for serious diseases such as multiple sclerosis, Parkinson's disease and Alzheimer's Harmo's disease.
GlaxoSmithKline's R&D investment in China has brought many China hospitals into the local drug development centers of excellence. GlaxoSmithKline has set up a clinical research center in China and cooperated with more than 30 medical schools/hospitals in more than 200 drug research and development projects. It is recognized as a leader in the treatment of hepatitis B, type 2 diabetes, asthma and mental illness. In 2003, GlaxoSmithKline set up an OTC R&D center in Tianjin.
GlaxoSmithKline China has three business areas: prescription drugs, vaccines and consumer health products, providing patients with dozens of preventive and therapeutic drugs, covering hepatitis, asthma and chronic obstructive pulmonary disease, depression and anxiety, tumors, antibiotics, antipyretic and analgesic drugs, skin and sexually transmitted diseases, gastrointestinal tract, cardiovascular and AIDS; At the same time, it provides oral care products, nutritious health drinks and other consumer health products for the public.